Interestingly, in the mouse tumor model with IFI27 overexpression, the efficacy of PD-1 antibody monotherapy was not significantly different from that of the combination therapy with gemcitabine and PD-1 antibody. This evidence concerns the gene PDCD1 and neoplasm.